GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Nivalis Therapeutics Inc. (NVLS) [hlAlert]

Rating:
Buy NVLS
down 68.73 %

Novellus Systems, Inc. (NVLS) rated Buy with price target $56.25 by Needham

Posted on: Friday,  Feb 3, 2012  8:25 AM ET by Needham

Needham rated Buy Nivalis Therapeutics Inc. (NASDAQ: NVLS) on 02/03/2012, when the stock price was $49.41. Since
then, Nivalis Therapeutics Inc. has lost 68.73% as of 08/27/2015's recent price of $15.45.
If you would have followed this Needham's recommendation on NVLS, you would have lost 68.73% of your investment in 1301 days.

Novellus Systems Inc. manufactures, markets and services advanced deposition and surface preparation equipment for today's advanced integrated circuits. The company's products are designed for high-volume production of advanced, leading-edge semiconductor devices at the lowest possible cost. (Company Press Release)

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/3/2012 8:25 AM Buy
None
49.41 56.25
as of 12/31/2012
1 Week   
1 Month   
3 Months   
1 YTD down  -2.17 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/15/2011 8:25 AM Buy
None
42.09 51.75
12/6/2011 8:25 AM Buy
None
36.01 40.00
9/1/2011 8:25 AM Buy
None
27.70 32.00
7/12/2011 8:25 AM Buy
None
32.96 38.00
4/28/2011 8:25 AM Buy
None
32.17 41.00
7/10/2009 8:25 AM Buy
None
17.94 22.00
12/10/2008 9:25 AM Hold
None
12.80 12.00
10/24/2007 9:25 AM Buy
None
28.09 37.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy